Chemotherapy-Induced Nausea and Vomiting (CINV) Global Market Report 2024: Key Players, Demand Patterns And Forecasts 2033 | Pfizer Inc., Roche Holding AG, Merck & Co. Inc., AbbVie Inc

The Business Research Company has updated its global market reports, featuring the latest data for 2024 and projections up to 2033

The Business Research Company offers in-depth market insights through Chemotherapy-Induced Nausea and Vomiting (CINV) Global Market Report 2024, providing businesses with a competitive advantage by thoroughly analyzing the market structure, including estimates for numerous segments and sub-segments.

Market Size And Growth Forecast:
The chemotherapy-induced nausea and vomiting (cinv) market size has grown strongly in recent years. It will grow from $2.69 billion in 2023 to $2.92 billion in 2024 at a compound annual growth rate (CAGR) of 8.4%. The growth in the historic period can be attributed to growth in chemotherapy use, improved antiemetic agents, clinical guidelines, patient advocacy.

The chemotherapy-induced nausea and vomiting (cinv) market size is expected to see strong growth in the next few years. It will grow to $3.88 billion in 2028 at a compound annual growth rate (CAGR) of 7.4%. The growth in the forecast period can be attributed to personalized medicine, advances in antiemetic agents, telehealth and remote monitoring, health equity initiatives. Major trends in the forecast period include combination antiemetic therapies, supportive care services, digital health tools, survivorship care.

Get Free Sample Of This Report-
https://www.thebusinessresearchcompany.com/sample.aspx?id=13031&type=smp

Market Segmentation:
The main types of forms of chemotherapy-induced nausea and vomiting (CINV) are injectables, oral and transdermal patches. Injectables are chemicals that are injected into the body to have various effects. The various drug classes are 5-HT3 receptor antagonists, neurokinin-1 receptor antagonists, corticosteroids, cannabinoids and others and various emetogenic risks are highly emetogenic chemotherapy (HEC), moderately emetogenic chemotherapy (MEC) and low emetogenic chemotherapy (LEC). The various distribution channels are CINV hospitals, cancer research institutes, retail pharmacies, online pharmacies and drug stores applied in gynecology, urology, gastrointestinal surgery and others.

Major Driver - Rising Cancer Prevalence Spurs Growth In The Chemotherapy-Induced Nausea And Vomiting (CINV) Market
The increasing prevalence of cancer is expected to propel the growth of chemotherapy-induced nausea and vomiting (CINV) market going forward. Cancer is when some cells in the body develop uncontrolled and spread to other body regions. As cancer cases continue to grow, there is a greater incentive to develop more effective and targeted anti-emetic treatments to alleviate CINV, a distressing side effect of chemotherapy. This heightened focus on CINV management has led to advancements in understanding its underlying mechanisms and developing novel therapies. For instance, in January 2023, according to the American Cancer Society (ACS), a US-based volunteer health organization committed to cancer eradication, in the United States, it is anticipated to be 1.9 million new cancer cases (approximately 5,370 cases per day) and 609,820 cancer deaths (about 1,670 deaths per day) in 2023. Therefore, the increasing prevalence of cancer will drive the chemotherapy-induced nausea and vomiting (CINV) market.

Competitive Landscape:
Major players in the chemotherapy-induced nausea and vomiting (cinv) market are Pfizer Inc., Roche Holding AG, Merck & Co. Inc., AbbVie Inc., Novartis AG, AstraZeneca PLC, GlaxoSmithKline PLC, Baxter International Inc., Teva Pharmaceuticals Industries Ltd., Bausch Health Companies Inc., Eisai Co. Ltd., Jazz Pharmaceuticals PLC, Ono Pharmaceutical Co. Ltd., Dr. Reddy's Laboratories Ltd., Kyowa Kirin Inc., Amneal Pharmaceuticals Inc., Mundipharma International Limited, Insys Therapeutics Inc., Lupin Limited, Helsinn Holding S.A., Heron Therapeutics Inc., Camurus AB, Cadila Pharmaceuticals Limited, Acacia Pharma Ltd., Soligenix Inc.

Get Access To The Full Market Report -
https://www.thebusinessresearchcompany.com/report/chemotherapy-induced-nausea-and-vomiting-cinv-global-market-report

Top Trend - Leading Companies In The Cinv Market Pioneering Transdermal Delivery System (TDS) Innovations
Major companies operating in the chemotherapy-induced nausea and vomiting (CINV) market are working on new product innovations, such as transdermal delivery systems (TDS), to meet the customer requirements in the market. A transdermal delivery system (TDS) is a drug delivery system that allows the controlled release of a medication through the skin for systemic absorption. For instance, in April 2021, Starton Therapeutics Inc., a US-based biotechnology company, announced the FDA approval for STAR-OLZ transdermal delivery system (TDS) to treat chemotherapy-induced nausea and vomiting (CINV). STAR-OLZ is a multi-day olanzapine transdermal delivery system (TDS) covering the duration of the five-day CINV therapy. Independent double-blind trials have revealed that olanzapine is a potent antiemetic, outperforming other standard-of-care therapies, including NK1 receptor antagonists, regarding nausea management. STAR-OLZ previously completed Phase 1 in-human bioavailability (BA) trials, demonstrating that the transdermal patch has acceptable local tolerability during a 5-day dosing interval and provides roughly 60% less medication than the oral version.

The Table Of Content For The Market Report Include:
1. Executive Summary
2. Chemotherapy-Induced Nausea and Vomiting (CINV) Market Characteristics
3. Chemotherapy-Induced Nausea and Vomiting (CINV) Market Trends And Strategies
4. Chemotherapy-Induced Nausea and Vomiting (CINV) Market - Macro Economic Scenario
5. Chemotherapy-Induced Nausea and Vomiting (CINV) Market Size And Growth
…..
27. Chemotherapy-Induced Nausea and Vomiting (CINV) Market Competitor Landscape And Company Profiles
28. Key Mergers And Acquisitions
29. Future Outlook and Potential Analysis
30. Appendix
The Business Research Company has updated its global market reports, featuring the latest data for 2024 and projections up to 2033

The Business Research Company offers in-depth market insights through Chemotherapy-Induced Nausea and Vomiting (CINV) Global Market Report 2024, providing businesses with a competitive advantage by thoroughly analyzing the market structure, including estimates for numerous segments and sub-segments.

Market Size And Growth Forecast:
The chemotherapy-induced nausea and vomiting (cinv) market size has grown strongly in recent years. It will grow from $2.69 billion in 2023 to $2.92 billion in 2024 at a compound annual growth rate (CAGR) of 8.4%. The growth in the historic period can be attributed to growth in chemotherapy use, improved antiemetic agents, clinical guidelines, patient advocacy.

The chemotherapy-induced nausea and vomiting (cinv) market size is expected to see strong growth in the next few years. It will grow to $3.88 billion in 2028 at a compound annual growth rate (CAGR) of 7.4%. The growth in the forecast period can be attributed to personalized medicine, advances in antiemetic agents, telehealth and remote monitoring, health equity initiatives. Major trends in the forecast period include combination antiemetic therapies, supportive care services, digital health tools, survivorship care.

Get Free Sample Of This Report-
https://www.thebusinessresearchcompany.com/sample.aspx?id=13031&type=smp

Market Segmentation:
The main types of forms of chemotherapy-induced nausea and vomiting (CINV) are injectables, oral and transdermal patches. Injectables are chemicals that are injected into the body to have various effects. The various drug classes are 5-HT3 receptor antagonists, neurokinin-1 receptor antagonists, corticosteroids, cannabinoids and others and various emetogenic risks are highly emetogenic chemotherapy (HEC), moderately emetogenic chemotherapy (MEC) and low emetogenic chemotherapy (LEC). The various distribution channels are CINV hospitals, cancer research institutes, retail pharmacies, online pharmacies and drug stores applied in gynecology, urology, gastrointestinal surgery and others.

Major Driver - Rising Cancer Prevalence Spurs Growth In The Chemotherapy-Induced Nausea And Vomiting (CINV) Market
The increasing prevalence of cancer is expected to propel the growth of chemotherapy-induced nausea and vomiting (CINV) market going forward. Cancer is when some cells in the body develop uncontrolled and spread to other body regions. As cancer cases continue to grow, there is a greater incentive to develop more effective and targeted anti-emetic treatments to alleviate CINV, a distressing side effect of chemotherapy. This heightened focus on CINV management has led to advancements in understanding its underlying mechanisms and developing novel therapies. For instance, in January 2023, according to the American Cancer Society (ACS), a US-based volunteer health organization committed to cancer eradication, in the United States, it is anticipated to be 1.9 million new cancer cases (approximately 5,370 cases per day) and 609,820 cancer deaths (about 1,670 deaths per day) in 2023. Therefore, the increasing prevalence of cancer will drive the chemotherapy-induced nausea and vomiting (CINV) market.

Competitive Landscape:
Major players in the chemotherapy-induced nausea and vomiting (cinv) market are Pfizer Inc., Roche Holding AG, Merck & Co. Inc., AbbVie Inc., Novartis AG, AstraZeneca PLC, GlaxoSmithKline PLC, Baxter International Inc., Teva Pharmaceuticals Industries Ltd., Bausch Health Companies Inc., Eisai Co. Ltd., Jazz Pharmaceuticals PLC, Ono Pharmaceutical Co. Ltd., Dr. Reddy's Laboratories Ltd., Kyowa Kirin Inc., Amneal Pharmaceuticals Inc., Mundipharma International Limited, Insys Therapeutics Inc., Lupin Limited, Helsinn Holding S.A., Heron Therapeutics Inc., Camurus AB, Cadila Pharmaceuticals Limited, Acacia Pharma Ltd., Soligenix Inc.

Get Access To The Full Market Report -
https://www.thebusinessresearchcompany.com/report/chemotherapy-induced-nausea-and-vomiting-cinv-global-market-report

Top Trend - Leading Companies In The Cinv Market Pioneering Transdermal Delivery System (TDS) Innovations
Major companies operating in the chemotherapy-induced nausea and vomiting (CINV) market are working on new product innovations, such as transdermal delivery systems (TDS), to meet the customer requirements in the market. A transdermal delivery system (TDS) is a drug delivery system that allows the controlled release of a medication through the skin for systemic absorption. For instance, in April 2021, Starton Therapeutics Inc., a US-based biotechnology company, announced the FDA approval for STAR-OLZ transdermal delivery system (TDS) to treat chemotherapy-induced nausea and vomiting (CINV). STAR-OLZ is a multi-day olanzapine transdermal delivery system (TDS) covering the duration of the five-day CINV therapy. Independent double-blind trials have revealed that olanzapine is a potent antiemetic, outperforming other standard-of-care therapies, including NK1 receptor antagonists, regarding nausea management. STAR-OLZ previously completed Phase 1 in-human bioavailability (BA) trials, demonstrating that the transdermal patch has acceptable local tolerability during a 5-day dosing interval and provides roughly 60% less medication than the oral version.

The Table Of Content For The Market Report Include:
1. Executive Summary
2. Chemotherapy-Induced Nausea and Vomiting (CINV) Market Characteristics
3. Chemotherapy-Induced Nausea and Vomiting (CINV) Market Trends And Strategies
4. Chemotherapy-Induced Nausea and Vomiting (CINV) Market - Macro Economic Scenario
5. Chemotherapy-Induced Nausea and Vomiting (CINV) Market Size And Growth
…..
27. Chemotherapy-Induced Nausea and Vomiting (CINV) Market Competitor Landscape And Company Profiles
28. Key Mergers And Acquisitions
29. Future Outlook and Potential Analysis
30. Appendix

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

About The Business Research Company
The Business Research Company (www.thebusinessresearchcompany.com) is a market intelligence firm that pioneers in company, market, and consumer research. Located globally, TBRC's consultants specialize in various industries including manufacturing, healthcare, financial services, chemicals, and technology. The firm has offices located in the UK, the US, and India, along with a network of proficient researchers in 28 countries.

This release was published on openPR.